Acute Coronary Syndrome Market Research Report - Forecast to 2027

Acute Coronary Syndrome Market Research Report by Type (Unstable Angina, Nstemi), by Diagnosis (Blood Tests, Imaging, Stress Test), Treatment (Medication, Surgery), End-User (Hospitals & Clinics, Diagnostic Centers) - Forecast Till 2027

ID: MRFR/Pharma/4326-HCR | February 2021 | Region: Global | 100 pages         

Acute Coronary Syndrome Market

Acute Coronary Syndrome Market is expected to register a CAGR of 5.32% with USD 14,910.28 Million by 2030

Segmentation

By Type Unstable Angina Nstemi
By Diagnosis Blood Tests Imaging Stress Test
By Treatment Medication Surgery
By End-User Hospitals & Clinics Diagnostic Centers

Key Players

  • Boehringer Ingelheim International GmbH (Germany)
  • Johnson & Johnson Services
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Portola Pharmaceuticals
  • AbbVie Inc. (U.S.)
  • AstraZeneca (U.K)
  • Amgen Inc. (U.S.)
  • Bayer AG (Germany)
  • DAIICHI SANKYO COMPANY
  • LIMITED. (Japan)

Drivers

  • The increasing prevalence of coronary heart disease
  • Growing geriatric population
  • Growing obese population
Speak to Analyst Request a Free Sample

Acute Coronary Syndrome Market Scenario


Acute Coronary Syndrome market is Expected to grow at an approximate CAGR of 10.4% during the forecast period. The acute coronary syndrome is a medical condition characterized by a sudden slowing or blockage of blood supply to the heart. The acute coronary syndrome can be exampled by myocardial infarction. Indigestion, dyspnea, diaphoresis, and unexplained fatigue are some of the common symptoms associated with the syndrome. The increasing prevalence of coronary heart disease and growing geriatric population is expected to be a major driver for the market growth during the forecast period. According to the Centers for Disease Control and Prevention in 2017, approximately 366,000 people died due to coronary heart disease within the Americas in 2015. Moreover, according to the World Health Organization, people who age 65 years or more are projected to grow from 524 million in 2010 to nearly 1.5 billion by 2050. Additionally, factors such as rising prevalence of diabetes and growing obese population boost the acute coronary syndrome market growth. However, lack of awareness, high therapeutic surgery cost, and low per capita healthcare expenditure in the middle and low-income countries are estimated to restrain the market growth during the forecast period. As per a study published in the Brazilian Journal of Cardiovascular Surgery, the average cost for coronary artery bypass graft surgery, per patient, was estimated to be about USD 7,992.55 in 2017.


Segmentation


The acute coronary syndrome market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, the market is segmented into unstable angina, ST-Elevation Myocardial Infarction (STEMI), Non-ST-Elevation Myocardial Infarction (NSTEMI), and others. On the basis of diagnosis, the market is categorized into blood tests, imaging, stress test, and others. The imaging segment is sub-segmented into Myocardial Perfusion Imaging (MPI), Computerized Tomography (CT) angiogram, echocardiogram, coronary angiogram, and others. On the basis of treatment, the market is segmented into medication, surgery, and others. The medication segment is sub-segmented into thrombolytics, nitroglycerin, antiplatelet drugs, beta blockers, statins, surgery, and others. The antiplatelet drugs segment is further segmented into aspirin, clopidogrel, prasugrel, and others. The beta blockers segment is further segmented into metoprolol, nadolol, and others. The statins segment is further segmented into atorvastatin, simvastatin, and others. The surgery segment is sub-segmented into angioplasty and stenting, coronary bypass surgery, and others. On the basis of end-user, the market is segmented into hospitals and clinics, diagnostic centers, academic institutes, and others.


Regional Analysis


The Americas dominates the acute coronary syndrome market owing to the rising prevalence of coronary heart diseases and presence of a well-developed healthcare sector within the region. Moreover, increasing healthcare expenditure and presence of market players within the region boost the market.


Europe stands second in the acute coronary syndrome market due to the increasing availability of funds for research, a huge patient population, and a well-developed healthcare sector. According to the Heart U.K., there were approximately 404,000 hospital admissions due to coronary heart diseases in England during 2012 to 2013. Moreover, growing geriatric and obese population provides favorable backgrounds for market growth within the region.


Asia Pacific is the fastest growing region for the market due to the presence of developing economies such as India, China, Australia, and others within the region. Moreover, a huge patient population, rising healthcare expenditure, and a rapidly developing healthcare sector fuel the market growth.


The Middle East and Africa has the least share in the acute coronary syndrome market. This can be attributed to the low per capita healthcare expenditure and stringent government policies, especially within the African region. On the hand, the Middle East holds a majority of the market due to a well-developed healthcare sector and huge healthcare expenditure.


Key players


The key players for the acute coronary syndrome market are Boehringer Ingelheim International GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc.  (U.S.), AstraZeneca (U.K), Amgen Inc. (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.K), Sanofi (Paris), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), and others.


Intended Audience



  • Pharmaceutical Companies

  • Biotechnological Institutes

  • Government and Private Laboratories

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   10.4% (2020-2027)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GmbH (Germany), Johnson & Johnson Services, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Portola Pharmaceuticals, Inc. (U.S.), AbbVie Inc. (U.S.), AstraZeneca (U.K), Amgen Inc. (U.S.), Bayer AG (Germany), DAIICHI SANKYO COMPANY, LIMITED. (Japan), Eli Lilly and Company (U.S.), GlaxoSmithKline Plc. (U.K), Sanofi (Paris), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.)
  Key Market Opportunities

  • Increasing healthcare expenditure
  • increasing availability of funds for research
  •   Key Market Drivers

  • The increasing prevalence of coronary heart disease
  • Growing geriatric population
  • Growing obese population


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Acute Coronary Syndrome Market is projected to grow at a 10.4 % CAGR between 2020-2027..

    The Americas is expected to lead the Acute Coronary Syndrome Market.

    Different end users of Acute Coronary Syndrome Market include academic institutes, diagnostic centers, hospitals and clinics, and others.

    Growing obese population and rising prevalence of diabetes is adding market growth.

    High cost and lack of awareness may limit market growth.